Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Remains On Track With Telaprevir For 2010 NDA, 2011 Anticipated Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Looking to be the leader in STAT-C combo therapy for hepatitis C, Vertex also plans trial testing telaprevir with VX-222.

You may also be interested in...



Vertex Advances Toward Telaprevir Approval

The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.

Vertex Advances Toward Telaprevir Approval

The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.

Prospect Of Predictive Gene Test Grips Developers Of Hepatitis C Drugs

The discovery of a gene marker that foretells the effectiveness of current standard-of-care therapy in hepatitis C offers a new tool for drug development and a potential guide for clinicians

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel